On November 24th, 2015 Orthopeutics was awarded another US patent. This latest issued patent covers tissue crosslinking for treatment of snoring and obstructive sleep apnea (OSA). Additional patents are pending in this treatment area.
In November of 2014, Orthopeutics launched a new entity responsible for all non-spine, human research, development, and commercialization built upon Orthopeutics’ core technologies. Crosscoat Medical is currently raising grant (SBIR Phase II) and investment funding to develop and commercialize revolutionary micro-invasive and device coating delivered tissue modification treatments. Orthopeutics new mission will be limited to intellectual property growth and management.
Orthopeutics was awarded $245k SBIR Phase I grant from the National Heart, Lung and Blood Institute (NHLBI) to investigate new injectable treatment for snoring and sleep apnea.
Orthopeutics’ 8th US patent #8,450,276 will issue May 28, 2013 – covers increasing biological viability for regeneration of spinal discs